AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Bioethicist joins the FDA to help oversee pediatric clinical trials: part of congressional mandate.(Practice Trends)(Sara Goldkind)
Bioethicist Dr. Sara Goldkind has joined the Food and Drug Administration's Office of Pediatric Therapeutics in the Office of the Commissioner.
In 2001, when Congress reauthorized the statutory incentives for pediatric clinical trials, it mandated that the FDA establish the Office of Pediatric Therapeutics and include a bioethicist on staff.
The American Academy of Pediatrics drafted ethical guidelines for the study of drugs in pediatric patients, and several of the academy's recommendations were incorporated into the FDA's regulations. As part of her charter, Dr. Goldkind "will work with those regulations that relate to studies that are done with greater than minimal risk for generalizable information rather than for direct patient information or direct patient benefit."
She also will sit on several established FDA ethics panels, including a neonatal ethics working group and a pediatrics working group. Dr. Goldkind will work with the FDA's Office of Human Research Protections, Health and Human Services, and the National Institutes of Health, as ...
- FDA announces renowned pediatric ethicist Robert M. Nelson, M.D., to join...
- Press release article from: M2 Presswire September 15, 2006 700+ words
...M.D., to join Office of Pediatric Therapeutics; Represents significant...will join FDA's Office of Pediatric Therapeutics and will be responsible...Director of the Office of Pediatric Therapeutics at FDA. "We are...
- New Office at FDA. (Pediatric Briefs).(Office of Pediatric Therapeutics)
- Magazine article from: Pediatric News Tucker, Miriam E. August 1, 2001 700+ words
...Drug Evaluation and Research, has proposed a new Office of Pediatric Therapeutics. It is aimed at addressing the "explosive growth...Woodcock said, noting that she hopes the new office will be up and running by the beginning of fiscal...
- InfaCare Names Paul J. Marangos CEO and Director; New Company Will Focus on...
- Press release article from: PR Newswire March 21, 2002 700+ words
...Marangos stated, "InfaCare is an exciting new company and will be unique in its business focus on Neonatal and Pediatric therapeutics. The unmet medical needs in this area are profound and I look forward to the challenge." InfaCare Pharmaceutical...
- John Post named COO of company focused on neonatal and pediatric therapeutics.
- Newspaper article from: Health & Medicine Week June 14, 2004 700+ words
2004 JUN 14 - (NewsRx.com & NewsRx.net) -- Dr. Robert A. Vukovich, chairman and founder of InfaCare Pharmaceutical Corp., announced that John R. Post has joined the company as COO. InfaCare is a sister company to WellSpring Pharmaceutical Corp. in Neptune, New Jersey. "The board of directors is
- InfaCare Names Horace Hertz CFO; New Company Will Focus on Neonatal and...
- Press release article from: PR Newswire April 19, 2002 700+ words
...company's leading SEC practice in California; and Partner in charge of the middle market department in the Orange County office of Deloitte & Touche. Most recently, Mr. Hertz was hired as Acting Chief Executive Officer of a computer storage company...
- InfaCare Names John R. Post COO; Company Focus on Neonatal and Pediatric...
- Press release article from: PR Newswire May 20, 2004 700+ words
NEPTUNE, N.J., May 20 /PRNewswire/ -- Dr. Robert A. Vukovich, Chairman and Founder of InfaCare Pharmaceutical Corporation, announced today that John R. Post has joined the Company as Chief Operating Officer. InfaCare is a sister company to WellSpring Pharmaceutical Corporation in Neptune, NJ. "The
- FDA Approves Risperdal for Two Psychiatric Conditions in Children and...
- Press release article from: M2 Presswire August 23, 2007 700+ words
...Dianne Murphy, M.D., director of FDA's Office of Pediatric Therapeutics. "These data have permitted the identification...Titusville, N.J. For more information: FDA Office of Pediatric Therapeutics www.fda.gov/oc/opt/default.htm...
- FDA Panel Evaluates SSRIs, Risk Of Suicidal Thoughts.
- Magazine article from: BIOWORLD Today November 3, 2009 700+ words
...Monday, Dianne Murphy, the FDA's director, office of pediatric therapeutics, said the medical community's knowledge of pediatric...president of medical affairs in the Collegeville office, who told the panels that there were increased...
